Yes, boosting certain molecules shows genuine promise in preventing and even reversing dementia. Recent research published in March 2026 shows that restoring NAD+ levels in mouse brains reversed markers of advanced Alzheimer’s disease—a finding that could eventually translate into new treatments for people experiencing cognitive decline. Scientists have identified multiple molecular pathways that break down with age, and the emerging evidence suggests that restoring these molecules might slow, stop, or reverse the damage driving dementia.
This article explores the most promising molecular targets currently being studied, what makes them effective, which ones are entering human trials, and what limitations researchers still face. Over the past year, dementia research has shifted from a purely preventive focus to actually reversing existing disease markers. The breakthrough discoveries aren’t hypothetical—they’ve been tested in living brains, published in peer-reviewed journals, and are moving into clinical trials. Understanding which molecules show the most potential and how they work can help you evaluate future treatments and understand the science behind headlines you’ll likely hear more about.
Table of Contents
- What is NAD+ and why does restoring it matter for Alzheimer’s?
- Alpha-Ketoglutarate and the restoration of memory
- Drug candidates in human trials—CT1812 and NU-9
- How these molecules and drugs actually work in the brain
- The major limitations and what researchers still don’t know
- The recently discovered “death switch”—a hidden protein pairing in Alzheimer’s
- The emerging landscape—from prevention to reversal
- Conclusion
- Frequently Asked Questions
What is NAD+ and why does restoring it matter for Alzheimer’s?
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in every living cell that plays essential roles in cellular energy production, DNA repair, and maintaining the health of mitochondria—the cell’s energy powerhouses. As we age, NAD+ levels naturally decline, and this depletion correlates with aging-related diseases, including Alzheimer’s and Parkinson’s. Scientists believe this decline isn’t just a side effect of aging—it’s a driver of neurodegeneration.
The March 2026 research showed something remarkable: when researchers artificially restored NAD+ levels in the brains of aging mice with advanced Alzheimer’s pathology, it reversed markers of disease progression. This wasn’t about slowing decline—it was about reversing damage that was already done. The study used mice with established amyloid plaques and tau tangles, the hallmark proteins that destroy brain cells in Alzheimer’s disease, and restoring NAD+ helped clear these toxic accumulations. However, this research remains in preclinical stages; we don’t yet know if the same mechanism will work in human brains or how to safely and effectively restore NAD+ levels in people.
Alpha-Ketoglutarate and the restoration of memory
Another molecule gaining serious attention is alpha-ketoglutarate, a natural compound that declines during aging. research published in January 2026 found that this molecule repairs key memory processes affected by Alzheimer’s disease by improving communication between brain cells. In mouse models, alpha-ketoglutarate restored early memory abilities that had been lost, suggesting it works through a different mechanism than NAD+—it focuses on the synapses, the connection points where neurons communicate.
What makes alpha-ketoglutarate particularly interesting is that it’s a natural aging-related molecule, meaning it’s not a foreign chemical but rather something your body produces throughout life. The limitation here is similar to NAD+: we’re still in preclinical research phases. The molecules that work in mice don’t automatically work in humans, particularly when dealing with a disease as complex as Alzheimer’s. Additionally, the challenge of getting these molecules across the blood-brain barrier—the protective layer that filters what enters brain tissue—remains a significant hurdle that researchers are still working to overcome.
Drug candidates in human trials—CT1812 and NU-9
While NAD+ and alpha-ketoglutarate represent natural molecules being studied, pharmaceutical researchers have taken different approaches by developing new drugs specifically designed to tackle Alzheimer’s pathology. CT1812, supported by nearly a decade of NIH-funded research, works by displacing toxic protein aggregates at synapses—essentially removing the debris that prevents neurons from communicating properly. The drug is currently in Phase 2B clinical trials, recruiting participants to test whether it can slow cognitive decline in people with early Alzheimer’s disease. NU-9 represents another promising approach.
It decreases toxic amyloid beta oligomers—smaller, more damaging versions of the amyloid protein that accumulate in Alzheimer’s brains. In mouse models, NU-9 dramatically reduced the damage caused by amyloid buildup, protecting brain cells from degeneration. The drug has already received FDA clearance to begin human clinical trials, though it was initially studied for ALS. These candidates show that targeting toxic proteins through drugs is moving from laboratory discovery into real human testing, though early-stage trials mean efficacy in humans remains unknown.
How these molecules and drugs actually work in the brain
Understanding mechanism helps explain why researchers are excited about these approaches. NAD+ primarily works through mitochondrial function and DNA repair—it helps cells maintain their energy and fix damage at the genetic level. Alpha-ketoglutarate focuses on synaptic communication, essentially helping neurons talk to each other more effectively. CT1812 and NU-9 work directly against the proteins that accumulate and poison the brain in Alzheimer’s disease.
A critical comparison: some molecules (like NAD+ and alpha-ketoglutarate) address the aging process itself, while drug candidates like CT1812 and NU-9 target specific Alzheimer’s pathology. This distinction matters because it suggests we might need different approaches for prevention versus treatment. Someone at risk of dementia but without symptoms might benefit most from molecules that address aging, while someone with early cognitive decline might benefit from drugs that attack the disease directly. The challenge is that no single approach has yet proven sufficient alone—researchers suspect combination therapies may ultimately be necessary.
The major limitations and what researchers still don’t know
Despite the excitement around these discoveries, significant gaps remain. First, all the molecular breakthroughs discussed here were discovered using mouse models. While mice are valuable for initial testing, human brains are vastly more complex, with different biology, longer lifespans, and different disease progressions. Something that reverses Alzheimer’s markers in a mouse might have minimal effect in a person, or it might cause unexpected side effects.
Second, researchers don’t yet understand optimal dosing, how long treatments need to last, when people should start them, or who will benefit most. Should someone start boosting NAD+ at age 40 as prevention, or only after cognitive decline begins? How long would treatment continue? These practical questions can only be answered through years of human trials. Additionally, the blood-brain barrier remains a formidable obstacle—even if a molecule is beneficial, getting enough of it into the brain to make a difference is scientifically difficult. Early promising discoveries have failed when researchers couldn’t solve this delivery problem.
The recently discovered “death switch”—a hidden protein pairing in Alzheimer’s
In March 2026, researchers made a striking discovery that adds another dimension to dementia prevention. They identified that two proteins—NMDAR and TRPM4—work together as what scientists describe as a “death switch,” a pairing that drives Alzheimer’s disease progression. This wasn’t previously understood as connected; it took advanced research techniques to reveal they work as a dangerous duo.
The significance is that scientists have now developed a compound capable of breaking apart this protein pair, and in initial studies, this disruption slowed disease progression, protected brain cells, and reduced amyloid buildup. This discovery exemplifies why dementia research remains active and evolving. Each breakthrough opens new therapeutic angles. However, this finding, like the others, remains in early stages—the compound has been tested in animal models and must now move through extensive human testing to determine if it’s safe and effective.
The emerging landscape—from prevention to reversal
The shift from prevention to reversal marks a fundamental change in how scientists approach dementia. For decades, research focused on stopping decline before it starts. Now, with molecules like NAD+ showing the ability to reverse existing damage, the field is asking whether early intervention—even in people without symptoms—could essentially halt or reverse the aging process in the brain. This opens possibilities that seemed impossible just years ago.
Looking forward, most experts expect that effective dementia prevention will likely involve combinations of approaches. Someone at genetic risk might take a molecule to support cellular aging (NAD+) combined with a drug targeting specific pathology (like CT1812), along with lifestyle factors. The next 5-10 years of human trials will determine which combinations work, for whom, and at what stage of cognitive decline they’re most effective. The molecules discussed here represent genuine scientific progress, not speculative fiction, but they also represent early chapters in a much longer story.
Conclusion
Yes, boosting specific molecules shows real promise in preventing and potentially reversing dementia, but the path from laboratory discovery to effective treatment requires years of careful human testing. The recent breakthroughs in NAD+, alpha-ketoglutarate, and innovative drugs like CT1812 and NU-9 represent our best current hope for addressing the underlying biology of Alzheimer’s disease rather than just managing symptoms. These aren’t cure-alls, and they won’t work for everyone, but they shift the conversation from inevitability to possibility.
If you’re interested in participating in the emerging clinical trials testing these approaches, or if you’re considering preventive strategies for yourself or a family member, discuss these developments with your healthcare provider. The research is moving quickly, and new trials are opening regularly. Understanding the science helps you evaluate headlines critically and make informed decisions about your brain health.
Frequently Asked Questions
Can I take NAD+ boosters now to prevent dementia?
Supplements claiming to boost NAD+ are available, but human clinical evidence for dementia prevention is limited. The recent breakthroughs showing NAD+ reverses damage in mice brains haven’t yet been tested in people. Talk with your doctor before starting supplements, especially if you take other medications.
How long before these treatments are available to the general public?
Drugs in Phase 2B trials (like CT1812) typically require 3-5 more years of testing before potential FDA approval, assuming they prove effective. Molecules like NAD+ and alpha-ketoglutarate that work in animals may require similarly long development timelines for human use.
Do lifestyle factors matter if these molecular treatments exist?
Yes. Even if molecular therapies eventually become available, exercise, cognitive engagement, quality sleep, Mediterranean-style diet, and social connection have their own evidence for supporting brain health. Effective prevention likely combines multiple approaches.
Which molecule is closest to becoming an available treatment?
CT1812 is furthest along, currently enrolling people in Phase 2B trials. NU-9 has FDA clearance for human trials but hasn’t yet published results from human studies. NAD+ and alpha-ketoglutarate remain in preclinical research.
Should I worry about side effects from these treatments?
All drugs have potential side effects that only become clear through human testing. Early animal studies suggest good safety profiles, but human side effects may emerge. This is exactly why clinical trials test both safety and efficacy carefully.
If I have early cognitive decline, should I enroll in a trial?
Discussing clinical trial options with a neurologist or memory specialist makes sense, especially if you have early symptoms. Trials typically have specific inclusion criteria, and participating could provide access to experimental treatments while advancing science.
